CVS Health Corporation (CVS) has agreed to acquire the entire outstanding shares of Aetna for a total consideration of $77bn.
The shareholders of the target company will be paid $145 a share in cash and issued 0.8378 CVS shares for each Aetna share held. The target company shareholders will hold 22% of the merged company, while the remaining will be held by the acquirer company shareholders.
The transaction will integrate the expertise of CVS and Aetna to redefine consumer healthcare experience and build a healthcare platform for individuals.
NeuroSearch has announced its intention to be sold to a potential buyer in 2018.
Based in Denmark, NeuroSearch is a biotechnology company involved in developing pharmaceuticals for the treatment of diseases and disorders.
The firm plans for voluntary liquidation in case it does not secure a satisfactory bid.
The net proceeds of liquidation are intended to be distributed to the shareholders.